Pharmacological Sciences Research Lab, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan, People's Republic of China.
BMC Complement Med Ther. 2022 Jun 13;22(1):158. doi: 10.1186/s12906-022-03629-7.
The 7β-(3-ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone (ECN), a sesquiterpenoid isolated from the Tussilago farfara Linneaus (Asteraceae), was evaluated against acute Carrageenan and chronic complete Freund's adjuvant (CFA)-induced arthritis in mice.
Acute and chronic arthritis were induced by administering Carrageenan and CFA to the intraplantar surface of the mouse paw. Edema, mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia were assessed in the paw. Similarly, histological and immunohistological parameters were assessed following arthritis induced by CFA. Antioxidants, inflammatory cytokines, and oxidative stress markers were also studied in all the treated groups.
The ECN treatment significantly attenuated edema in the paw and elevated the nocifensive threshold following induction of this inflammatory model. Furthermore, ECN treatment markedly improved the arthritis index and distress symptoms, while attenuating the CFA-induced edema in the paw. ECN treatment also improved the histological parameters in the paw tissue compared to the control. At the same time, there was a significant reduction in edema and erosion in the ECN-treated group, as measured by radiographic analysis. Using the Comet's assay, we showed that ECN treatment protected the DNA from chronic CFA-induced arthritis. Immunohistochemistry analysis showed a marked decrease in the expression level of p-JNK (phosphorylated C-Jun N-terminal kinase), NF-κB (Nuclear factor-kappa B), COX-2 (Cyclooxygenase-2), and TNF-α (Tumour necrosis factor-alpha) compared to the CFA-treated group. Biophysical analysis involving molecular docking, molecular dynamics simulations, and binding free energies of ECN were performed to explore the underlying mechanism.
ECN exhibited significant anti-inflammatory and anti-arthritic activity against Carrageenan and CFA-induced models.
从款冬( Asteraceae )中分离得到的 7β-(3-乙基-顺-巴豆酰氧基)-1α-(2-甲基丁酰氧基)-3,14-去氢泽诺酮(ECN)被评估用于治疗急性角叉菜胶和慢性完全弗氏佐剂(CFA)诱导的关节炎。
通过向小鼠足底表面注射角叉菜胶和 CFA 来诱导急性和慢性关节炎。在足底评估水肿、机械性痛觉过敏、机械性痛觉超敏和热痛觉超敏。同样,在 CFA 诱导关节炎后评估组织学和免疫组织化学参数。在所有治疗组中还研究了抗氧化剂、炎症细胞因子和氧化应激标志物。
ECN 治疗显著减轻了诱导该炎症模型后的足水肿,并提高了伤害性阈值。此外,ECN 治疗显著改善了关节炎指数和痛苦症状,同时减轻了 CFA 诱导的足水肿。与对照组相比,ECN 治疗还改善了足组织的组织学参数。同时,通过放射分析,在 ECN 治疗组中观察到水肿和侵蚀明显减少。使用彗星试验,我们表明 ECN 治疗保护了 DNA 免受慢性 CFA 诱导的关节炎的影响。免疫组化分析显示,与 CFA 处理组相比,p-JNK(磷酸化 C-Jun N 末端激酶)、NF-κB(核因子 kappa B)、COX-2(环氧化酶-2)和 TNF-α(肿瘤坏死因子 alpha)的表达水平显著降低。进行了涉及分子对接、分子动力学模拟和 ECN 结合自由能的生物物理分析,以探索潜在的机制。
ECN 对角叉菜胶和 CFA 诱导的模型表现出显著的抗炎和抗关节炎活性。